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Abstract
Background: In spite of the implementations of several strategies, tuberculosis (TB) is overwhelmingly a serious global
public health problem causing millions of infections and deaths every year. This is mainly due to the emergence of
drug-resistance varieties of TB. The current treatment strategies for the drug-resistance TB are of longer duration, more
expensive and have side effects. This highlights the importance of identification and prioritization of targets for new
drugs. This study has been carried out to prioritize potential drug targets of Mycobacterium tuberculosis H37Rv based on
their flow to resistance genes.
Methods: The weighted proteome interaction network of the pathogen was constructed using a dataset from STRING
database. Only a subset of the dataset with interactions that have a combined score value ≥770 was considered.
Maximum flow approach has been used to prioritize potential drug targets. The potential drug targets were obtained
through comparative genome and network centrality analysis. The curated set of resistance genes was retrieved from
literatures. Detail literature review and additional assessment of the method were also carried out for validation.
Results: A list of 537 proteins which are essential to the pathogen and non-homologous with human was obtained
from the comparative genome analysis. Through network centrality measures, 131 of them were found within the close
neighborhood of the centre of gravity of the proteome network. These proteins were further prioritized based on their
maximum flow value to resistance genes and they are proposed as reliable drug targets of the pathogen. Proteins which
interact with the host were also identified in order to understand the infection mechanism.
Conclusion: Potential drug targets of Mycobacterium tuberculosis H37Rv were successfully prioritized based on their
flow to resistance genes of existing drugs which is believed to increase the druggability of the targets since inhibition
of a protein that has a maximum flow to resistance genes is more likely to disrupt the communication to these genes.
Purposely selected literature review of the top 14 proteins showed that many of them in this list were proposed as
drug targets of the pathogen.
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Background
Mycobacterium tuberculosis (Mtb) which is the etiological
agent of tuberculosis (TB) remains one of the main
health threats of human by being the cause of morbidity
and mortality to millions every year [1]. According to
the estimates of WHO global tuberculosis report of
2014, there were 9 million people who developed TB
and 1.5 million who died from the disease in 2013 [2].
One of the major factor which makes the management,
control and eradication programs of the diseases chal-
lenging is the emergence of multi-drug resistance tuber-
culosis (MDR-TB) and extensive drug resistance
tuberculosis (XDR-TB) [3, 4]. MDR-TB is resistance to
at least isoniazid and rifampicin which are the two most
powerful anti-TB drugs [5, 6]. XDR-TB, in addition to
being resistance to at least isoniazid and rifampicin, is
also resistance to at least three of the six main classes of
second-line drugs (SLDs) [7]. The WHO estimate
showed that 3.6 % of the new and 20.2 % of previously
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treated TB cases have had MDR-TB and an estimated of
9.0 % of patients with MDR-TB had XDR-TB in 2013
[2]. Various strategies have been widely implemented to
tackle the problem of resistance in the past including:
rotation of antibiotic combinations, identification of less
mutable targets, search for new chemical entities for
known targets, use of virulence factors as targets and
'phenotypic conversion', which aims to inhibit the resist-
ance mechanism employed by the bacterium [8]. Even
with the existence of these important counter measures,
the available statistics indicates that resistance forms are
still on the rise [9]. Moreover, SLDs are being used for
the current treatments of MDR-TB [10]. These treat-
ments are of longer duration, less effective, more toxic,
and more expensive than isoniazid and rifampicin. This
shows the importance of further investigations to iden-
tify reliable therapeutic targets and prioritize the existing
ones for the discovery of new drugs.
Various computational methods were used to identify
drug targets for the most studied strain of TB, Myco-
bacterium tuberculosis H37Rv. Structure-based drug
target identification is one of these approaches [11, 12].
Its drawback is limited availability of protein 3D struc-
tures. Another common computational method uses
global centrality measures such as closeness/between-
ness on molecular interaction networks to identify the
targets. A node with higher value of closeness/between-
ness centrality would be considered as initial candidates
for drug targets [13]. For instance, list of proteins were
identified as potential drug targets of Mycobacterium
tuberculosis H37Rv through network centrality analysis
on protein-protein interaction network of the pathogen
[14]. These proteins were also non-homologous to hu-
man. The global network centrality measures are mainly
based on shortest paths without considering other paths
that could be important to spread information in the cel-
lular network [11]. This is the common critic with respect
to these measures but there are counter arguments. One
of which is shortest paths yield a higher coverage than
observed directly neighbours locally from protein-protein
interaction data. Moreover, it has been hypothesised that
shortest paths are the most feasible paths that can be
taken by proteins to communicate with each other [9].
Measure of betweenness centrality based on random
walks has been suggested as improved versions of these
measures [15]. Even though it still gives more weight to
the short paths, it tries to incorporate all paths between
nodes. There are also computational studies and databases
which use integrated approaches with series of filters to
identify new drug targets for the pathogen [16, 17]. All of
these methods didn’t consider the influence of newly iden-
tified targets to drug resistance genes of first line and SLDs
to tackle the problem of resistance. However, there are ef-
forts to understand emergence of resistance mechanisms
from wholistic system perspective in which co-targets have
been suggested for effective antibacterial drugs [9, 18, 19].
The main idea is that the target-co-target combination
disrupts the network to reduce the emergence of drug
resistance thus allowing the main drug to kill the bacteria.
In spite of the importance of co-targets to tackle the emer-
gence of drug resistance, it is not helpful in treating
already developed drug resistance. That is one of the main
reasons why we need new primary targets than co-targets
to tackle this problem.
In this analysis, maximum flow approach has been
proposed to further prioritize potential drug targets of
Mycobacterium tuberculosis H37Rv based on their flow
to resistance genes of existing drugs. Since this approach
is based on the flow, it is not expected to be affected by
biasness towards shortest paths like the common global
centrality measures. More importantly, the inhibition of
a protein which has a maximum flow to the resistance
genes of the existing drugs is expected to disrupt the com-
munication to these genes. So, this further prioritization is
believed to be a rational approach to deal with the prob-
lem of resistance at the initial stage of drug discovery
process.
Methods
A set of highly reliable potential drug targets P and disease
resistance genes set G of Mycobacterium tuberculosis
H37Rv have been taken as input. The modified version of
Melak and Gakkhar [14] has been used to identify poten-
tial drug target set P. They were obtained from a compre-
hensive comparative genome and network centrality
analysis. The complete genome of Mycobacterium tuber-
culosis H37Rv was retrieved from Tuberculosis database
[20, 21]. BLAST search of the retrieved protein coding
genes was carried out against Database of Essential Genes
(DEG) to identify proteins which are essential for the sur-
vival and growth of the pathogen [22–24]. The resulted
proteins were then compared against the non-redundant
database with an e-value threshold cut off set to 0.005
[25]. The search was also restricted to H. sapiens because
the objective was to find only those proteins, which do not
have detectable human homologues to prevent host tox-
icity. The refined proteins obtained from comparative gen-
ome analysis were prioritized and a set P of 137 proteins
have been identified. The prioritization was based on net-
work centrality measures and these proteins found at the
centre of gravity of the proteome network. A protein is
said to be at the centre of gravity of a functional network
of interest if its betweenness measure is above the total
number of shortest paths expected to pass through it [26].
This cut off has been effectively used by the authors in
identification of drug targets.
The drug resistance genes list G is a curated list of 82
genes involved in both intrinsic and extrinsic drug
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resistance mechanisms of Mycobacterium tuberculosis
H37Rv identified from two published literatures [17, 18].
In those analyses, they scanned the available biological
literatures to obtain information about associations of
individual proteins with drug resistance and verified
manually to include in the drug resistance list.
Subsequently weighted protein-protein interaction net-
work of the pathogen was constructed by using a dataset
retrieved from Search Tool for the Retrieval of Interacting
Genes/Proteins (STRING) database. STRING is a dedi-
cated resource of physical and functional protein-protein
interactions [27]. It acts as a meta-database which maps
all interaction evidence onto a common set of genomes
and proteins by integrating information from numerous
sources, including experimental repositories, computa-
tional prediction methods and public text collections. A
combined score is assigned for every pair of protein-
protein association in the database [28]. This score is com-
puted by combining the probabilities from several pieces
of evidence and correcting for the probability of randomly
observing an interaction. The higher combined score value
for interacting pair of proteins means the interaction is
being supported by several pieces of evidence. It has been
shown in a recent comprehensive study that the protein-
protein interactions of Mycobacterium tuberculosis
H37Rv generated from STRING are of low quality consist-
ing of a significant amount of false positives and false neg-
atives [29]. However, the study also indicated that a subset
of this dataset (with combined score ≥ 770) is more reli-
able with greater portion of it having correlated gene ex-
pression profiles and coherent informative Gene Ontology
(GO) term annotations in both interaction partners. Thus,
this subset of interaction dataset has been used in this
analysis and the combined score of the pair of interacting
proteins has been assigned as a weight of interaction [30].
It is hypothesized that a higher weight value for a pair of
interacting proteins denotes there would be more flow.
On the other hand, the weight zero means that the two
proteins are not interacting pairs so no flow can pass
through them.
In order to understand the general functional organization
of interacting proteins, the statistical properties of the
generated proteome network were characterized by dif-
ferent measures such as; degree distribution, character-
istic path length and clustering coefficient.
One of the most basic properties of a vertex ni is its
degreeki, defined as the number of edges adjacent to the
vertex. The degree distribution p (k) is the measure of the
proportion of edges in the network having degree k [31].
The distancedij between any two vertices ni and nj in a
network is the length of the shortest path between them.
It is the minimal number of edges that need to be tra-
versed to travel from vertex ni tonj. The path between
two nodes doesn’t necessarily have to be unique since
there could be several alternative paths with the same
path length. Thus, the characteristic path length is the
average shortest path of overall pairs of nodes in the net-
work with n vertices [31].
Clustering coefficient is a measure of the probability
of two nodes with a common neighbour to be con-
nected [31]. It is an indicator of local cohesiveness and
internal structure of the given network. In a given ver-
tex ni with ki neighbours of an undirected network,
there exist Emax ¼ ki ki −1ð Þ2 possible edges between the
neighbors. Thus, clustering coefficient Ci of vertex ni is
the ratio of the actual number of edges Ei between the
neighbors to the maximal numberEmax;
Ci ¼ 2Eiki ki −1ð Þ
Mean clustering coefficient is then computed as the
average of clustering coefficients of all vertices.
The main focus of this analysis is to further prioritize
potential drug targets of Mycobacterium tuberculosis
H37Rv based on their maximum flow to resistance
genes. This has been done through identifying the max-
imum flow between the candidate proteins P and dis-
ease genes G. Maximizing the flow from the candidate
proteins to the resistance genes seems to be reasonable
since understanding the efficient communications in
the biological networks can be helpful to design treat-
ment mechanisms for the problem of resistance in a
systematic and rational way. The following are the con-
straints applied to specify the problem into the classical
maximum flow problem [11]:
Constraint 1 The protein-protein interaction is a bi-
directional edge.
In the protein-protein interaction network, flow direc-
tion is one of the most important features. However,
almost all the outcomes of current high-throughput
techniques for protein-protein interactions mapping are
usually supposed to be non-directional. Thus, the protein-
protein interaction in this analysis has been considered as
bidirectional edge.
Constraint 2 A dummy sink node is created to connect
all resistance genes with the capacity of these edges set
to infinity.
Constraint 3 All candidate proteins are connected to a
dummy source node and the capacity of these edges are
set to infinity.
Since infinite value is not practical, the value greater than
the maximum possible flow which is the product of max-
imum degree and maximum capacity has been assigned.
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Constraint 4 If a resistance gene is also a candidate pro-
tein, to avoid unfair advantage, it has only been connected
to dummy source node but not to the dummy sink node.
Let V be a set of nodes representing proteins, E be a set
of edges representing interactions between proteins, and
the nodes s and t be the source and sink nodes respect-
ively. Further, c is a nonnegative capacity of the edges.
Then, for a weighted interaction network G = (V, E, s, t, c),
the size is denoted as n = |V| and m = |E|. A flow f is a real
valued function on the edges and the excess value ef (v) is
the difference between the incoming and outgoing flows
to a node under consideration. A node v is said to be ac-
tive if v ∈V − {s, t}, d(v) < n and ef (v) > 0, and we call an
edge (v,w) admissible ifd(v) = d(w) + 1. The flow f satisfies
the following three constraints [32, 33]:
Capacity constraint : f v; uð Þ≤c v; uð Þ f or all v; uð Þ∈V  V
ð1Þ
Skew symmetry constraint : f v; uð Þ ¼ ‐f u; vð Þfor all v; uð Þ∈V  V
ð2Þ
Flow conservation constraint :
X
f u; vð Þ ¼ 0 f or all u; vð Þ∈V
− s; tf g
ð3Þ
The problem here is to find the maximum flow from
the dummy source node to dummy sink node. We wish
to achieve that by manipulating the preflow f on the net-
work satisfying constraints (1–3).
The following initializations have been made [32]:
The initial value of the flow f (v, u) is set to zero for all
(v, u) ∊ (V− {s}) × (V− {s}) and f (s,v) set to c(s, v) for allv ∊V.
The distance of a node d(v)to the sink node t is n for
v = s and zero for allv ∊ (V − {s}).
The excess flowef for the source node is the sum of
capacities of all of its edges and zero for all verticesv
∊ (V − {s, t}).
Once the initialization is complete, a repeated push
and relabel operations have been performed on active
nodes starting from the provided source node until there
are no more active nodes or the edges are saturated.
The Push (v,w) and Relabel (v) operations:
Push (v,w).
Applicability: v is active and (v,w) is admissible
Action: send δ =min(ef(v), uf) units of flow from v to w
Relabel (v).
Applicability: v is active and push (v,w) can’t be applied
Action: replace d(v) bymin{d(w) + 1|(v,w) ∈ Efor by n if ∄
(v,w) ∈ Ef}
An edge is said to be saturated if the flow on it can’t be
increased without violating the capacity constraint and re-
sidual otherwise [33]. The residual capacity uf of an edge
(v,w) is the amount by which the flow can be increased.
The push and relabel operations modify the preflow f and
labelling d. A push from v to w increases f (v,w) andef (w)
by δ ¼ min ef vð Þ;uf
 
, and decreases f (w, v) and ef (v)
by the same amount. A relabeling of v sets its label to the
largest value allowed by the valid labeling constraints.
FIFO algorithm has been used to maintain the set of active
nodes in which the front node is always selected for dis-
charging and the newly active node is added to the rear of
the queue [33]. Gap relabeling has been used as a distance
relabeling heuristic which is based on the following obser-
vation [31]. If we have an integer g and 0 < g < n. Suppose
at a certain stage of the algorithm there are no nodes with
distance label g but there are nodes v with g < d (v) < n.
This implies that the sink is not reachable from any of
these nodes. Therefore, the labels of such nodes may be
increased to n (note that these nodes will never be active).
Cytoscape 3.0.2 was used for the generation of statistical
properties of the network [34]. It is an open source soft-
ware platform for visualizing complex networks and inte-
grating these with any type of attribute data. The network
centrality measures were computed using CytoNCA, a
plug-in of Cytoscape [35]. The maximum flow approach
was implemented using adjacency list of First In First Out
(FIFO) push-relabel maximum flow with gap relabeling
heuristic. For the purpose of proof of correctness, a graph
obtained from an analysis by Schroeder et al. (2004) has
been used [36]. The progression of experiments of this
analysis has been shown in Fig. 1.
Results and discussion
Discovery of new drugs of TB is one of the solutions to
deal with the problem of drug-resistance more systematic-
ally [2]. In this study, potential drug targets of Mycobacter-
ium tuberculosis H37Rv were further prioritized based on
their maximum flow to the resistance genes to identify
those targets in which their inhibition would disrupt com-
munications to these resistance genes in the proteome
interaction network. The initial input set of potential drug
targets of the pathogen, consisting of a list of 137 proteins,
is obtained from systematically integrated comparative
genome and network centrality analysis. These proteins
are believed to be more reliable targets since they are es-
sential for the survival and growth of the pathogen, non
homologous to human and found within the close neigh-
bourhood of the centre of gravity of the protein-protein
interaction network of the pathogen. There are four types
of mechanisms of resistance for Mycobacterium tubercu-
losis H37Rv: efflux pumps, target-modification, DNA repli-
cation and Horizontal Gene Transfer (HGT) [9]. A
curated list of 82 proteins involved in these drug resistance
mechanisms has also been taken as an input for the study.
Then, protein-protein interaction network was con-
structed based on the retrieved associations from STRING
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[27]. Only interactions with a combined score value ≥ 770
were considered in this analysis since they are verified as
more reliable dataset containing less false negatives and
false positives [28]. The resulting refined network contains
14,671 interactions among 3,487 proteins.
General statistical properties of the network which is
being used to describe essential properties have been
shown in Table 1. Characteristic path length is an im-
portant property of a network indicating one protein’s
influence on another with number of intermediate reac-
tions which would be useful to understand the efficiency
of communication of biological information. The corre-
sponding shortest path length distribution has been
shown in Fig. 2. Another important property of a net-
work is clustering coefficient and the clustering coefficient
of the resulted network is significantly higher than the
clustering coefficient of a random graph with the same
number of vertices (0.002). The degree distribution of
the resulted network has also been shown in Fig. 3. The
network exhibits scale-free property like many biological
networks in which the degree distribution of proteins
approximates a power law p (k) = k−γ, with the degree
exponent γ ~ 1.753. This means there are very small
number of highly connected nodes called hubs and a
vast majority of nodes with few connections.
In order to find the maximum flow from the potential
drug targets to the resistance genes and prioritize them
accordingly, we have defined the source and sink nodes.
Out of the 137 proteins taken as potential drug target set,
131 proteins were found in the resulted protein-protein
interaction network and these proteins were connected to
the dummy source node based on constraint 3. From the
curated list of 82 resistance genes, 78 were found in the
constructed protein-protein interaction network. Three of
Fig. 1 Progression of Experiments
Table 1 Statistical Properties of the Generated Network
Parameter Value
Number of nodes (n) 3487
Connected components 107
Network diameter 15
Average number of neighbours 8.415
Network density 0.002
Characteristic path length 5.655
Clustering coefficient 0.379
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them were also candidate drug targets and they have only
been connected to dummy source node based on con-
straint 4. Then the remaining 75 proteins (see Additional
file 1) were connected to a dummy sink node based on
constraint 2.
The maximum flows of each of 131 potential candidate
proteins to the dummy sink node have been identified and
they were sorted accordingly. We hypothesize that the
flows are used to quantify structural and biochemical sig-
nals flow from these candidate proteins to the molecular
components of the resistance machinery by which
inhibition of the newly proposed targets are expected to
have a better success in dealing with MDR and XDR TB.
Detail information of the maximum flow of each candi-
date protein is also provided as an Additional file 2.
In this prioritized list, proteins which interact with the
host were identified using a dataset retrieved from a
computational prediction of Homo Sapiens- Mycobacter-
ium tuberculosis H37Rv protein-protein interactions
[37]. This was carried out in order to understand the in-
fection mechanism of the pathogen. As it has been
shown in Table 2, 15 out of 131 proteins interact with
the host. The reason for the presence of only few over-
laps is due to the fact that the host–pathogen interaction
dataset is not comprehensive.
Candidate proteins at the top 10 % maximum flow as
lower limit of the 90th percentile which contain 14 pro-
teins (Table 3) were taken for further analysis. The targe-
tablity of a drug target depends on several factors which
include: essentiality to the growth and survival of the
pathogen, non homologous to the host, availability of 3D
structure and gene expression: a target would be desir-
able if it is expressed in the organism at least under dis-
ease conditions. The identified potential targets through
this analysis are obviously essential, non homologous to
human and found with in close neighbourhood of the
centre of gravity of the protein-protein interaction net-
work. Out of the top 14 proteins 5 of them have solved
3D structures. Structures of proteins of the pathogen
that don’t have experimentally solved crystal structures
can also be obtained using theoretically calculated struc-
tural models.
Literature review has been carried out for these top 14
proteins to find out if the result of this analysis is in line
with similar studies. All of the top 14 proteins are Trop-
ical Disease Research (TDR) validated targets for Myco-
bacterium tuberculosis H37Rv. TDR Targets database is
a dedicated database to facilitate the rapid identification
and prioritization of molecular targets for drug develop-
ment, focusing on pathogens responsible for neglected
Fig. 2 Shortest Path Length Distribution
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human diseases [16]. It has also been observed that
some of these proteins were reported as potential drug
targets of the pathogen by various studies. An integrated
approach of an interactome, reactome and genome-scale
structural analysis to identify potential drug targets of
Mycobacterium tuberculosis is a comprehensive ap-
proach among these studies which implements multi-
step filters. The final list of potential drug targets from
this study are likely to be successful since the pipeline
incorporates a network analysis of the protein-protein
interaction, a flux balance analysis of the reactome, ex-
perimentally derived phenotype essentiality data, se-
quence analyses and a structural assessment of
targetablity [17]. From our list of top 14 candidate pro-
teins, secY (Rv0732), katG (Rv1908c), gltB (Rv3859c)
and sirA (Rv2391) are among the final list of potential
targets identified by this study [17]. katG (Rv1908c) is a
validated drug target and multifunctional enzyme, exhi-
biting both a catalase, a broad-spectrum peroxidase, and
a peroxynitritase activities. secY (Rv0732) is significantly
more useful as a drug target since it has been involved
in the emergence of resistance in the interactome by me-
diating the flow of information from the existing drugs
to the resistance machinery. Rv2455c is among the en-
zymes identified as drug targets of the pathogen by using
in silico analysis of Metabolic Pathways [38]. DNA
Fig. 3 Node Degree Distribution
Table 2 Potential targets interact with human
Protein Functional class Max-flow
Rv0732 cell wall and cell processes 49050
Rv1908c virulence, detoxification, adaptation 33297
Rv1599 intermediary metabolism and respiration 30402
Rv2455c intermediary metabolism and respiration 27485
Rv2150c cell wall and cell processes 23472
Rv2534c information pathways 20846
Rv1712 intermediary metabolism and respiration 20292
Rv2987c intermediary metabolism and respiration 17639
Rv1415 intermediary metabolism and respiration 16970
Rv3601c intermediary metabolism and respiration 16574
Rv2553c cell wall and cell processes 12177
Rv3921c cell wall and cell processes 12106
Rv1602 intermediary metabolism and respiration 11326
Rv1611 intermediary metabolism and respiration 10147
Rv2538c intermediary metabolism and respiration 7630
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polymerase III β sliding clamp’s ability to function with
diverse DNA repair proteins and cell cycle-control pro-
teins make it a potential drug target [39]. ftsZ (Rv2150c),
a bacterial tubulin homologue involved in essential cell
division, is considered as an attractive target to develop
novel anti-TB drugs, as well as new broad-spectrum
antibacterial agents [40].
The schematic diagram which depicts the concept about
the mechanism of resistance to the existing drugs and the
way to tackle the problem with the newly proposed targets
has been shown in Fig. 4. Decades-old drugs are no longer
effective in killing drug resistance mycobacterium tuber-
culosis which leads to the requirement of new targets to
tackle the problem. The newly proposed targets in this
analysis are central to interactome network, essential to
the growth and survival of the pathogen, and have higher
maximum flow value to resistance genes which increases
the druggability since the inhibition of the target would
disrupt the communication.
Assessment of the method
Validation is one of the challenges in identifying drug
targets of TB using computational methods mainly due
to the unavailability of standard dataset. It would also be
ideal to have negative dataset in order to assess their
performances. However, such data is not available be-
cause of the lack of interest of researchers in validating
them [11]. Yeh et al. [11] evaluated the performance of
maximum flow approach in identifying drug targets of
prostate cancer. This has been carried out through a
comparison with other approaches: degree, network en-
tropy, betweenness, closeness and random walk [11].
They obtained the highest mean average precision for
maximum flow approach which indicates the method
has a better performance than the stated approaches.
In this analysis, validated drug targets for currently
existing drugs and essential non- homologous proteins
were taken to assess the performance of the method.
The 8 clinically used drugs for the treatment of tubercu-
losis interact with 35 different proteins in the proteome
network of the pathogen [18]. Out of these proteins, 34
of them were found in the generated proteome network
and they were taken as validated drug targets. From the
comparative analysis, 572 proteins were identified. Out
of them 537 found in the generated network and taken
as essential and non-homologous proteins. Then, the
average ranks of the validated drug targets on the non-
homologous essential proteins were computed based on
their maximum flow value to resistance genes. A lower
average rank indicates a better performance. The abso-
lute count of validated drug targets in the top 1 % of
non-homologous essential proteins (practically in the
top 5 proteins), in the top 5 % (practically in the top 26
proteins), in the top 10 % (practically in the top 53 pro-
teins), in the top 15 % (practically in the top 80 proteins)
and in the top 20 % (practically in the top 107 proteins)
were reported (Table 4). For instance, in the top 1 %, the
method identified 2 validated drug targets.
Conclusion
In this study, highly reliable potential drug targets and re-
sistance genes to the existing drugs of Mycobacterium tu-
berculosis H37Rv were taken as an input and maximum
flow approach has been used to prioritize these proteins
based on the flow value of each protein to resistance genes.
The potential drug target proteins taken as an input are es-
sential to the survival and growth of the pathogen, non-
Table 3 Top 14 candidate protein drug targets of Mycobacterium tuberculosis H37Rv
Gene Symbol Locus Functional class Max-flow Cross reference (PDB)
rpoA Rv3457c information pathways 70861
rpsC Rv0707 information pathways 61418
rplJ Rv0651 information pathways 61319
secY Rv0732 cell wall and cell processes 49050
gdh Rv2476c intermediary metabolism and respiration 36008
katG Rv1908c virulence, detoxification, adaptation 33297 1SFZ;1SJ2;2CCA;2CCD;4C50;4C51;
glcB Rv1837c intermediary metabolism and respiration 31666 2GQ3;3S9I;3S9Z;3SAD;3SAZ;3SB0;
hisD Rv1599 intermediary metabolism and respiration 30402
korA Rv2455c intermediary metabolism and respiration 27638
rpoZ Rv1390 information pathways 27485
gltB Rv3859c intermediary metabolism and respiration 26942
dnaN Rv0002 information pathways 24226 3P16;3RB9;
sirA Rv2391 intermediary metabolism and respiration 23588 1ZJ8;1ZJ9;
ftsZ Rv2150c cell wall and cell processes 23472 1RLU;1RQ2;1RQ7;2Q1X;2Q1Y;4KWE;
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homologous to human proteins and found near to the cen-
ter of gravity of interactome network. Resistance genes are
curated list of reported genes which are involved in both
intrinsic and extrinsic drug resistance mechanisms of
Mycobacterium tuberculosis H37Rv [9]. Using maximum
flow approach as a new method on proteome interactome
network of the pathogen has an importance of considering
the flow instead of shortest paths like other global network
centrality measures. There are many well established
criteria for assessing the targetablity of potential drug tar-
get proteins of various diseases which include essentiality,
non homologous to the host, availability of solved struc-
ture and gene expression under disease conditions. How-
ever to our knowledge there is no comprehensive effort to
incorporate the influence of drug targets on resistance
genes of diseases like Mycobacterium tuberculosis H37Rv
as criteria of druggablity. This leads to the possibility of in-
cluding the influences of newly proposed targets on resist-
ance genes as a new concept to assess the druggability of a
target. We successfully prioritised potential drug targets
based on their flow to resistance genes of the existing
drugs of the pathogen. This increases the success rate of
the potential drug targets in the rational drug discovery
process. A detail literature review of the top 14 drug tar-
gets has also showed that many of these proteins have
been suggested as highly reliable targets.
Additional files
Additional file 1: Resistance genes. A curated list of resistance genes
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